CONFERENCE COVERAGE SERIES
Keystone Symposium: Neurodegenerative Diseases: New Molecular Mechanisms
Keystone Resort, Keystone, Colorado, U.S.A.
17 – 22 February 2009
Keystone: Death Receptor Ligand—New Role for APP, New Model for AD? PAPER RETRACTED.
At the Keystone symposium on Wednesday, debate on the last plenary talk continued around the dinner table and well into the poster session...
Keystone: Partners in Crime—Do Aβ and Prion Protein Pummel Plasticity?
Finding Aβ oligomers bound to cellular prion (PrPc) was absolutely unexpected...
Keystone: Longevity, Insulin-like Growth Factor Signaling, and Aβ Toxicity
You can never turn back the clock, but you can protect against the dementia risk of advancing age...
Keystone: Pulse-Chasing AD Biomarkers, Snaring γ-Secretase Targets
Two things you can find on any Alzheimerologist’s wish list are better drug targets and better diagnostics...
Keystone: Tau, Huntingtin—Do Prion-like Properties Play a Role in Disease?
Could prion-like properties of the microtubule binding protein tau explain the phenotypic diversity and the characteristic progression of different tauopathies...
Keystone: Toxic or Truant—Keeping Tau on Track
Is it time to stop focusing on Aβ monotherapies for Alzheimer disease (AD) and start looking to tau therapies as well?...
Keystone: More Than Mere Nucleotides—miRNAs as Master Regulators, Part 1
If a keystone was to be found at the recent symposium held 17-22 February at Keystone, Colorado, it may well have been microRNAs (miRNAs)...
Keystone: More Than Mere Nucleotides—miRNAs as Master Regulators, Part 2
MicroRNAs were a common emerging theme at the recent Keystone Symposium, “Neurodegenerative Diseases: New Molecular Mechanisms,” held 17-22 February at Keystone, Colorado...